This trial is studying how well osimertinib, surgery, and radiation therapy work together to treat patients with EGFR mutated non-small cell lung cancer.
- Non-Small Cell Lung Cancer
- Stage IIIB Lung Cancer
- Stage IV Lung Cancer
- Stage IVB Lung Cancer
- Stage IVA Lung Cancer
1 Primary · 5 Secondary · Reporting Duration: Up to 4 years
Side Effects for
2 Treatment Groups
Group II (no LCT)
1 of 2
Group I (LCT)
1 of 2
173 Total Participants · 2 Treatment Groups
Primary Treatment: Osimertinib · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 12 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How extensive is the participation of individuals in this research endeavor?
"Affirmative. According to information available on clinicaltrials.gov, this research is actively enlisting participants; the protocol was first distributed in January 17th 2018 and most recently adjusted on September 22nd 2022. The trial necessitates 143 individuals from 4 sites for completion." - Anonymous Online Contributor
Is there still an opportunity to be a participant in this trial?
"As per clinicaltrials.gov, this medical trial is presently recruiting patients. The experiment was first announced on January 17th 2018 and the most recent update occurred on September 22nd 2022." - Anonymous Online Contributor
What verifiable evidence exists that demonstrates Osimertinib's safety for treatment?
"Considering the lack of evidence demonstrating its efficacy, our team at Power gave Osimertinib a safety rating of 2." - Anonymous Online Contributor
What is the breadth of locales in which this experiment is being conducted?
"At present, 4 medical centres across America are enrolling patients for this clinical trial. In addition to Houston, Denver and San Francisco, there is another clinic located in a nearby city. To reduce travel requirements it would be advisable to select the centre closest to you if you decide to participate." - Anonymous Online Contributor
Can you outline the previous research conducted on Osimertinib?
"Osimertinib was initially studied in 2013 at Research Site and has since been the focus of 169 completed clinical trials. There are presently 101 active studies occurring, with many of these being conducted out of Houston, Texas." - Anonymous Online Contributor
Is this an innovative research effort?
"AstraZeneca sponsored the earliest clinical trial of Osimertinib in 2013, involving 603 participants. After successful Phase 1 & 2 trials were completed, there are now 101 active studies for this drug occurring across 1059 cities in 51 countries worldwide." - Anonymous Online Contributor